injection that will be utilized in positron emission tomography (PET) scans of PSMA-positive lesions in patients with suspected metastases who are eligible for initial definitive treatment. In addition, it also evaluates individuals with prostate cancer who have a high blood prostate-specific antigen level and are suspected of having a recurrence.
The Australian Therapeutic Goods Administration has already authorized the equipment. According to the business, it enhances imaging capabilities for diagnosing metastatic prostate cancer and identifying the most suitable treatment options for patients. The announcement comes as the business prepares to launch and commercialize its first product in the United States.
According to Christian Behrenbruch, Managing Director and CEO, this marks the beginning of a new era for patient and clinicians access to gallium-based PSMA-PET imaging. Dr Behrenbruch explained the benefits of the latest imaging technology. He said, “Improved imaging can provide physicians with the insights to determine the most appropriate treatment pathway and give patients in the U.S. access to a specific and sensitive imaging tool for the detection of prostate cancer throughout the body”.
Furthermore, according to the statement from Dr Oliver Sartor, Medical Director of the Tulane Cancer Center, Telix’s products and services provide healthcare providers with a degree of flexibility and accessibility that are not previously seen in this class of goods. With the clearance from the US Food and Drug Administration and the Australian Therapeutic Goods Administration, the business is currently moving on with marketing authorisation applications for Illuccix in the European Union, Canada, and other countries worldwide.
